Summary
Each year about 33,000 individuals in the United States are
diagnosed with pancreatic cancer, and more than 60,000 in Europe.
Because early detection of pancreatic cancer is difficult, only few
patients survive for five years after diagnosis, and complete
remission still extremely rare. It's poor prognosis, is due to the lack of
early diagnostic and therapeutic modalities. Researchers at the
University of Nebraska Medical Center have discovered that
pancreatic cancer cells over express a specific protein, PD2, that
plays a key role in regulation of differentiation and in the
maintenance of the neoplastic state. Based on this discovery,
researchers have developed novel methods for early detection of
PD2 over expression by pancreatic adenocarcinoma as well as a
treatment option that will inhibit PD2 over expression and thus
restrain pancreatic cancer growth and metastasis with minimal
systemic and/or local toxicity.

Market Value
The gene encoding for PD2 represents a valuable therapeutic target
in the differential diagnosis and therapy of pancreatic
adenocarcinoma. This technology will detect and treat pancreatic
cancer in patients in earliest developmental stage. This technology
can be used as a direct diagnostic tool as well as routine scheduled
pancreatic cancer preventative examination tool.

Features and Benefits
• Diagnosis of pancreatic cancer in its earliest developmental
stage
• Highly selective and effective inhibition of pancreatic cancer
growth and metastasis
• Minimal systemic and local toxicity
• Efficient diagnostic and therapeutic tool that can be applied to
prevention and treatment of pancrea

Patent Issued

(TID - 77)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.